Dose related effectiveness of alpha interferon in chronic myelogenous leukemia.

Gastl, G; Aulitzky, Q; Tilg, H; Huber, H; Hausmaninger, H; Seewann, HL; Coser, C; Prinoth, P; Huber, C; Blut. 1987; 54(4): 251-252.

Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions.

Schulz, TF; Vogetseder, W; Mitterer, M; Neumayer, HP; Myones, BL; Stauder, R; Greil, R; Böck, G; Feichtinger, H; Huber, H; Mol Immunol. 1988; 25(11):1053-1061

Vindesine-mitoxantrone (VM) versus vindesine-4″-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial.

Hausmaninger, H; Lehnert, M; Onkologie. 1988; 11(1): 59-60.

Treatment of herpes zoster. Recombinant alpha interferon versus acyclovir.

Duschet, P; Schwarz, T; Soyer, P; Henk, A; Hausmaninger, H; Gschnait, F; Int J Dermatol. 1988; 27(3): 193-197.

Tumour cell morphometry and response to chemotherapy in ovarian cancer.

Weger, AR; Ludescher, C; Mikuz, G; Hausmaninger, H; Lindholm, J; Lancet. 1988; 2(8618): 1020-1021.

Steroid hormone receptors and prognosis in breast cancer.

Daxenbichler, G; Forsthuber, EP; Marth, C; Kemmler, G; Wiegele, J; Margreiter, R; Müller, L; Hausmaninger, H; Manfreda, D; Dapunt, O; Breast Cancer Res Treat. 1988; 12(3): 26-73.

Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour.

Stauder, R; Greil, R; Schulz, TF; Thaler, J; Gattringer, C; Radaskiewicz, T; Dierich, MP; Huber, H; Clin Exp Immunol. 1989; 77(2): 234-238.

In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies.

Greil, R; Fasching, B; Huber, H; Lab Invest. 1989; 60(4): 574-582.

Immunohistology for quantification of normal bone marrow lymphocyte subsets.

Thaler, J; Greil, R; Dietze, O; Huber, H; Br J Haematol. 1989; 73(4):576-577

The value of morphometry to predict chemotherapy response in advanced ovarian cancer.

Weger, AR; Ludescher, C; Mikuz, G; Kemmler, G; Reitsamer, R; Hausmaninger, H; Lindholm, J; Pathol Res Pract. 1989; 185(5): 676-679.